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Abstract
Background S-1 is first-line therapy for advanced gastric
cancer in Asia and is used with increased frequency in
Western counties. We conducted a meta-analysis to
investigate the efficacy and toxicity of S-1-based therapy
compared with 5-fluorouracil (5-FU)/capecitabine-based
therapy and S-1-based combination therapy compared with
S-1 monotherapy.
Methods MEDLINE, Embase, the Cochrane Central
Register of Controlled Trials, American Society of Clinical
Oncology meeting abstracts, European Society for Medical
Oncology meeting abstracts and ClinicalTrials.gov were
searched for randomized clinical trials until May 2015.
Data were extracted for overall survival (OS), progression-
free-survival (PFS), objective response rate (ORR) and
grade 1–2 and grade 3–4 adverse events. Stratified OS data
for subgroups were extracted.
Results S-1 was not different from 5-FU (eight studies,
n = 2788) in terms of OS [hazard ratio (HR) 0.93, 95 %
confidence interval (CI) 0.85–1.01] and PFS (HR 0.87,
95 % CI 0.73–1.04), whereas ORR was higher (risk ratio
1.43, 95 % CI 1.05–1.96). There was no subgroup differ-
ence in efficacy among Asian and Western patients, but in
Western patients S-1 was associated with a lower rate of
febrile neutropenia, toxicity-related deaths and grade 3–4
stomatitis and mucositis compared with 5-FU. S-1 showed
no difference in efficacy compared with capecitabine (three
studies, n = 329), but was associated with a lower rate of
grade 3–4 neutropenia and grade 1–2 hand–foot syndrome.
S-1-combination therapy was superior to S-1 monotherapy
(eight studies, n = 1808) in terms of OS (HR 0.76, 95 %
CI 0.65–0.90), PFS (HR 0.68, 95 % CI 0.56–0.82) and
ORR (risk ratio 1.20, 95 % CI 1.04–1.38) but was more
toxic. Survival benefit of S-1 combination therapy over S-1
monotherapy was most pronounced in patients with non-
measurable disease, diffuse-type histological features and
peritoneal metastasis.
Conclusions S-1 is effective and tolerable as first-line
therapy for advanced gastric cancer in both Asian and
Western countries.
Keywords Advanced gastric cancer  S-1 
Chemotherapy  Meta-analysis
Introduction
Fluoropyrimidines are the backbone of first-line therapy for
advanced gastric cancer [1, 2]. The novel fluoropyrimidine
S-1 has quickly become the standard of care in Asia, but
there is uncertainty about the role of S-1 in Western
countries. Although S-1 is used with increasing frequency
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in Western countries, it has not fully replaced 5-fluo-
rouracil (5-FU) and capecitabine. Meta-analyses have
shown a marginally significant prolonged survival time and
higher response rates for S-1 therapy compared with 5-FU
therapy [3–5] but not for S-1 therapy compared with
capecitabine therapy [6–9]. However, some of these
reviews included retrospective studies, which may lead to
bias of the overall effect observed or did not incorporate
the newest evidence in this field [10–15]. For example, in
addition to the FLAGS trial [16], which was conducted in
Western countries, the recently presented DIGEST trial
[11] can also shed light on the role of S-1 therapy in
Western patients.
The use of doublets of cytotoxic agents versus singlets is
associated with prolonged survival [17] and therefore S-1-
based combination therapy versus S-1 monotherapy has
been investigated in several large trials in Asia. Previous
meta-analyses have indicated that combination therapy
significantly prolonged survival over monotherapy, but
generally combination therapy was more toxic [18, 19].
However, the final results of four randomized studies,
including the pivotal START trial, which was the first
phase III trial to compare S-1 combined with a taxane with
S-1 alone, were not included in these reviews [12, 13, 20,
21]. Moreover, it is also still an open question if there are
predictive factors to define which patient subgroups will
benefit most from S-1 combination therapy compared with
S-1 monotherapy.
Therefore, the objectives of our study were to system-
atically review all available literature on randomized clin-
ical trials to investigate the efficacy and toxicity by means
of meta-analysis of S-1-based therapy compared with 5-FU-
and capecitabine-based therapy and of S-1-based combi-
nation therapy compared with S-1 monotherapy.
Methods
Study protocol
The protocol of this review has been published in the




For the searching of the electronic databases [MEDLINE,
Embase and Cochrane Central Register of Controlled Tri-
als (CENTRAL)], a sensitive search strategy without date
restriction was applied using the medical subject headings
of ‘S-1’ and ‘gastric cancer’; thereafter, the results were
filtered for clinical trials. ClinicalTrials.gov (http://www.
clinicaltrials.gov) was searched for the term ‘S-1’ within
the topic ‘stomach neoplasm’ and the results were filtered
for phase II and phase III trials. In addition, all meeting
abstracts from the American Society of Clinical Oncology
and European Society for Medical Oncology up to May
2015 were searched via http://www.ascopubs.org/search
and http://annonc.oxfordjournals.org/search, respectively,
for the following terms: ‘S-1’ and ‘gastric’. The full search
history is available in Document S1 in the electronic sup-
plementary material. Two reviewers (E.t.V. and M.S.)
reviewed the literature independently, and discrepancies
were resolved by discussion with an arbiter (N.H.M.) until
consensus was reached. This systematic review was per-
formed according to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA)
statement.
Inclusion criteria
Studies had to meet the following eligibility criteria: (1)
included patients with pathologically proven advanced
gastric cancer (recurrent or unresectable disease); (2) first-
line palliative (a) S-1-based therapy (monotherapy or
doublet therapy) compared with 5-FU- or capecitabine-
based chemotherapy (monotherapy or doublet therapy ) or
(b) S-1-based combination chemotherapy compared with
S-1 monotherapy; and (3) prospective phase II or phase III
randomized controlled trials.
Outcomes and data extraction
The primary efficacy outcome was overall survival (OS).
To identify potential predictive factors for the efficacy of
S-1 combination therapy compared with S-1 monotherapy,
subgroup data were extracted for OS if possible. Secondary
efficacy outcomes were progression-free survival (PFS)
and overall response rate (ORR), defined as the sum of both
partial and complete responses according to the Response
Evaluation Criteria in Solid Tumors (RECIST). Tolerabil-
ity outcomes comprised the incidence of adverse events
(AEs) divided into mild toxicity (grade 1–2 AEs) and
severe toxicity (grade 3–4 AEs). In all studies, AEs were
scored according to the National Cancer Institute Common
Toxicity Criteria (http://ctep.cancer.gov). Two reviewers
(E.t.V. and N.H.M.) were involved in data extraction;
discrepancies were resolved by discussion with an arbiter
(L.N.) until consensus was reached.
Study quality assessment
Two reviewers (E.t.V. and N.H.M.) independently exam-
ined the quality of all included studies using the Cochrane
risk of bias tool (Cochrane Handbook for Systematic
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Reviews of Interventions, version 5.1.0) until consensus
was reached. Studies with a high risk of bias were not
included in the analysis. Since the primary outcome, OS,
would not be influenced by the absence of a blinded
imaging review, this item was not scored as unknown or
high risk of bias for OS. Single-centre studies and studies
without a published full article were rated as unclear risk of
other possible bias. To assess the effect of study quality on
the pooled estimate, sensitivity analyses were conducted by
(1) omission of studies described in conference reports only
and (2) omission of studies stepwise according to unknown
risk of bias rating on one item, on two items and on three or
more items.
Statistical analysis
Pairwise meta-analyses using random-effect models were
conducted with the Metagen R package [22] and Review
Manager 5.3. For OS and PFS outcomes, hazard ratios
(HRs) and 95 % confidence intervals (CIs) were extracted
by the method described by Tierney et al. [23]. An HR less
than 1 indicates a beneficial effect for the experimental
arm, and an HR of 0.80 or less was considered clinically
meaningful [24]. In addition, stratified HRs for OS in the
patient subgroups were pooled with meta-analysis, and
subgroup differences were statistically tested with chi-
square tests. Risk ratios (RRs) were calculated for ORR (an
RR greater than 1 indicates a beneficial effect for the
experimental arm) and for event counts of grade 1–2 and
grade 3–4 toxicity in both arms (an RR less than 1 indi-
cates a beneficial effect for the experimental arm).
Statistical heterogeneity was tested with the Cochran Q
test and quantified by the I2 index. Substantial hetero-
geneity (I2 C 30 %) was explored by subgroup and sensi-
tivity analyses. We tested for funnel plot asymmetry by
regressing study outcomes on the standard error of the
effect size [25]. All analyses were based on the intention-
to-treat population of the included studies. All tests were
performed two-sided, and a P value of less 0.05 was con-
sidered statistically significant.
Results
Literature search and study quality
Three hundred and fifty-four unique references were
identified through our searching MEDLINE, Embase and
CENTRAL until May 2015, from which 326 were exclu-
ded after abstract screening, because of ineligibility
according to the criteria for this review. Of the 28 reports
remaining for full-text screening, four studies were eligible
to assess S-1-based versus 5-FU-based therapy [26–29],
two studies were eligible to assess S-1-based versus
capecitabine-based therapy [30, 31] ,and six studies were
eligible to assess S-1 combination therapy versus S-1
monotherapy [21, 32–35]. Searching ClinicalTrials.gov
and the American Society of Clinical Oncology and
European Society for Medical Oncology libraries provided
additional reports of four unpublished phase III studies [11,
12, 14, 15] and two phase II studies [10, 13]. The total
number of studies included was 18 (Fig. S1).
There were no major differences in study and patient
characteristics among the studies included (Table 1),
although one study included patients with diffuse gastric
cancer only [11]. For the primary outcome, seven studies
were rated as low risk of bias [28–34], whereas 11 studies
were rated as unclear risk of bias because of the lack of
information on one item (three studies) [12, 21, 35] or two
items (three studies) [20, 27] or abstract and insufficient
information for risk of bias assessment (five studies) [10,
11, 13–15] (Fig. S2).
S-1-based therapy versus 5-FU- and capecitabine-
based therapy
Eleven studies (n = 3135) were included in the meta-
analysis: 1636 patients received S-1-based therapy, 1334
patients received 5-FU-based therapy (eight studies) and
165 patients received capecitabine-based therapy (three
studies). Nine studies were conducted in Asia (n = 1745)
and two studies were conducted in Western countries
(n = 1372) (Table 1). We were able to extract OS and PFS
data from ten and six studies. respectively, whereas ORR
data were available from all 11 studies.
Compared with 5-FU-based therapy, S-1-based therapy
showed no difference in OS (HR 0.92, 95 % CI 0.82–1.03,
P = 0.16) and PFS (HR 0.88, 95 % CI 0.73–1.08,
P = 0.22), but there was a significant increase in ORR
(RR 1.43, 95 % CI 1.05–1.96, P = 0.02) (Fig. 1). No
statistically significant subgroup differences were found
between Asian and Western patients in terms of OS
(P = 0.85), PFS (P = 0.55) and ORR (P = 0.63) (Fig. 2).
In the Asian population, S-1-based therapy was superior in
terms of ORR compared with 5-FU-based therapy
(P = 0.02), whereas in the Western population, statistical
significance was not reached (P = 0.52). No significant
heterogeneity was detected for OS (I2 = 26 %, P = 0.23);
for both PFS and ORR, heterogeneity was present, with
I2 = 72 % (P\ 0.01) and I2 = 78 % (P\ 0.001).
cFig. 1 S-1-based therapy compared with 5-fluorouracil (5-FU)- and
capecitabine (Cap)-based therapy: a overall survival; b progression-
free survival; c overall response rate. CI confidence interval, Cis
cisplatin, df degrees of freedom, E effect, H heterogeneity, HR hazard
ratio, Lv leucovorin, Ox oxaliplatin, PTX paclitaxel, RR risk ratio, SE
standard error
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Compared with capecitabine-based therapy, S-1-based
therapy showed no difference in OS (HR 1.03, 95 % CI
0.79–1.35, P = 0.81), PFS (HR 0.76, 95 % CI 0.50–1.16,
P = 0.20) and ORR (RR 0.92, 95 % CI 0.67–1.27,
P = 0.61) (Fig. 2). No statistically significant heterogene-
ity was detected.
For both comparisons, sensitivity analysis showed that
the direction of the overall results was not influenced by
omission of studies reported in conference abstracts only,
by omission of studies stepwise according to their risk of
bias, or by omission of two studies that had leucovorin in
the 5-FU arm, which was the case in the studies of Sawaki
et al. [15] and Huang et al. [27]. This indicates that the
results are robust regarding study quality and concomitant
administration of leucovorin (Table S1).
For S-1 compared with 5-FU, data were available for
four haematological and 14 non-haematological grade 1–2
AEs and for five haematological and 16 non-haematolog-
ical grade 3–4 AEs (Table 2). In the Western subgroup,
S-1-based therapy showed significantly lower rates of
febrile neutropenia, toxicity-related deaths, grade 3–4
stomatitis and mucositis and grade 1–2 diarrhoea, stom-
atitis and alopecia compared with 5-FU-based therapy. The
rates of grade 1–2 neutropenia and hand–foot syndrome
were greater with S-1 than with 5-FU.
In the Asian subgroup, S-1-based therapy showed a
significantly increased incidence of grade 3–4 fatigue and
grade 1–2 abdominal pain but a lower incidence of grade
1–2 neutropenia, nausea and weight loss compared with
5-FU-based therapy. The incidence of febrile neutropenia,
serious AEs or toxicity-related deaths was not different
between both arms.
For S-1 compared with capecitabine, data were available
for four haematological and 13 non-haematological grade
1–2 AEs and for five haematological and 12 non-haema-
tological grade 3–4 AEs (Table 3). Lower rates of grade
3–4 neutropenia and grade 1–2 hand–foot syndrome were
found with S-1-based therapy compared with capecitabine-
based therapy. The incidence of febrile neutropenia, seri-
ous AEs or toxicity-related deaths was not different
between both arms.
S-1-based combination therapy versus S-1
monotherapy
For this comparison, eight studies (n = 1808) were inclu-
ded in the meta-analysis, with 927 and 881 patients in the
S-1 combination therapy group and the S-1 monotherapy
group, respectively. Four different combination therapies
were compared with S-1 monotherapy: S-1 plus cisplatin
therapy (n = 544 patients, three studies), S-1 plus oxali-
platin therapy (n = 190, two studies), S-1 plus taxane
therapy (n = 717, two studies) and S-1 plus irinotecan
therapy (n = 404, two studies). All studies were conducted
in Asia: three studies in China, four studies in Japan, and
one study in both Japan and Korea (Table 1). We extracted
the HRs and 95 % CIs from seven studies for OS and from
five studies for PFS. ORRs were available from all eight
studies.
The pooled estimates of S-1 combination therapy versus
S-1 monotherapy were superior for OS (HR 0.76, 95 % CI
0.65–0.89, P\ 0.001), PFS (HR 0.68, 95 % CI 0.56–0.82,
P\ 0.001) and ORR (RR 1.51, 95 % CI 1.32–1.74,
P\ 0.001) (Fig. 3). Subgroup analyses showed that ORR
was significantly better for all four combination therapies
and showed no evidence of heterogeneity (I2 = 0 %,
P = 0.95). However, only S-1 plus oxaliplatin therapy
showed significant estimates for both OS and PFS com-
pared with S-1 monotherapy, whereas OS was not signifi-
cant for S-1 combined with irinotecan, cisplatin or a
taxane. PFS was statistically significant for S-1 plus taxane
therapy, but not for S-1 plus cisplatin therapy or S-1 plus
irinotecan therapy.
Heterogeneity was explored in subanalyses and sensi-
tivity analyses (Table S2). For the cisplatin-based and
taxane-based subgroup analyses, the non-significant effect
might by due to some heterogeneity among the studies (OS
I2 = 45.0 %, P = 0.08; PFS I2 = 44 %, P = 0.11). When
studies were stratified according to region, a significant
subgroup difference between Chinese studies and Japanese
studies was found in OS (P\ 0.005). No subgroup dif-
ferences for region were found in PFS (P = 0.38) and
ORR (P = 0.88). Furthermore, no significant fluctuations
in the overall results were detected with sensitivity analysis
according to study quality and concomitant administration
of leucovorin, which was the case with the comparison of
S-1 plus cisplatin therapy with S-1 plus leucovorin therapy
in the study of Yamaguchi et al. [13].
Data were available for four haematological and 12 non-
haematological grade 1–2 AEs and for five haematological
and 11 non-haematological grade 3–4 AEs. Compared with
S-1 monotherapy, S-1-based doublets were associated with
an increased rate of grade 3–4 neutropenia, leucopenia and
stomatitis and with an increased rate of grade 1–2 leu-
copenia, anaemia, thrombocytopenia, lymphocytopenia,
anorexia, fatigue and alopecia (Table S3).
To identify subgroups that may benefit most from S-1
combination therapy compared with S-1 monotherapy,
three large phase III Japanese studies (n = 1248) reporting
a stratified analysis for OS could be used (Fig. 4) [32, 33].
cFig. 2 S-1-based therapy compared with 5-fluorouracil (5-FU)-based
therapy for Asian and Western patient subgroups: a overall survival;
b progression-free survival; c overall response rate. Cap capecitabine,
CI confidence interval, Cis cisplatin, df degrees of freedom, E effect,
H heterogeneity, HR hazard ratio, Lv leucovorin, PTX paclitaxel, RR
risk ratio, SE standard error
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Fig. 3 S-1-based combination
therapy compared with S-1
monotherapy: a overall
survival; b progression-free
survival; c overall response rate.
CI confidence interval, Cis
cisplatin, df degrees of freedom,
DTX docetaxel, E effect,
H heterogeneity, HR hazard
ratio, IRI irinotecan, Lv
leucovorin, NA not available,
Ox oxaliplatin, PTX paclitaxel,
RR risk ratio, SE standard error
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The pooled effect size for these three studies was HR 0.82
(95 % CI 0.72–0.93). A trend toward significant subgroup
differences in favour of S-1 combination therapy was found
in favour of patients with diffuse-type histological features
compared with patients with intestinal-type histological
features (P = 0.06; HR\ 0.80) and patients with mea-
surable disease compared with patients with non-measur-
able disease (P = 0.06; HR\ 0.80). Furthermore,
subgroups with peritoneal metastases showed a non-sig-
nificant but clinically relevant HR (0.80 or less) in favour
of S-1 combination therapy. No other potential predictive
factors were identified.
Publication bias
Funnel plots did not show significant asymmetry and
Egger’s test was not significant for S-1-based therapy
versus 5-FU/capecitabine-based therapy in terms of OS
(P = 0.75), PFS (P = 0.82), and ORR (P = 0.73) and for
S-1-based combination therapy versus S-1 monotherapy in
terms of OS (P = 0.08), PFS (P = 0.71) and ORR
(P = 0.96) (Figure S3).
Discussion
Previous meta-analyses have suggested that 5-FU may be
replaced by S-1 in first-line therapy for advanced gastric
cancer because of a survival benefit in favour of S-1 [3, 4].
Our updated meta-analysis does not confirm this finding.
Although a higher ORR was observed for S-1-based ther-
apy versus 5-FU-based therapy, OS and PFS were not
significantly prolonged. The pooled OS and PFS effect
sizes of the two recently conducted Western studies, the
FLAGS and DIGEST trials, were comparable to the pooled
OS and PFS effect sizes of all Asian studies. This suggests
that S-1 may have similar efficacy in both Western and
Asian patients. However, in Western patients S-1-based
therapy did have clear clinically relevant advantages in
terms of the toxicity profile over 5-FU-based therapy—
namely, lower rates of febrile neutropenia, toxicity-related-
deaths and grade 3–4 mucositis and stomatitis, whereas the
toxicity profiles of S-1 and 5-FU in Asian patients showed
no clinically relevant differences, except a higher rate of
grade 3–4 fatigue and lower rates of grade 1–2 neutropenia
and nausea. This indicates that S-1 is well tolerated in
Western patients with its current dosing as used in the
FLAGS and DIGEST trials.
Also, S-1 was not more effective than capecitabine in
Asian patients. In the West, it has been suggested that
capecitabine may be replaced by S-1 in the case of hand–
foot syndrome. This meta-analysis shows that the incidence
of grade 1–2 hand–foot syndrome was significantly lower
with S-1 than with capecitabine. We stress that hand–foot
syndrome specifically can have a severe impact on quality
of life, because capacitabine is usually given for a longer
time. Moreover, in a previous review which also included
studies in metastatic colorectal cancer, a significantly lower
rate of grade 3–4 hand–foot syndrome was observed for
S-1 (0.3 %) compared with capecitabine (3.1 %);
P\ 0.001 [7]. Also, in our meta-analysis there were fewer
observations of grade 3–4 hand–foot syndrome with S-1
(0.0 %) versus capecitabine (3.1 %), but the numbers were
too low to reach statistical significance. Because all cape-
citabine studies were conducted in Asia, we should inter-
pret our findings with caution for Western populations..
This is the first meta-analysis to examine the differential
efficacy of combination therapy and monotherapy in
patients with different baseline factors and can aid in
clinical decision making. Overall, we showed that S-1
combination therapy is more efficacious than S-1
monotherapy. Importantly, our meta-analysis of stratified
data from the three largest studies suggests that patients
with disease characteristics associated with poor prognosis,
such as non-measurable lesion, diffuse-type histological
features and peritoneal metastasis, may have increased
benefit from combination therapy.
The pooled result for the OS benefit of taxane combi-
nations was not convincing because of heterogeneity.
However, the HR (0.73) may be considered clinically
meaningful and the PFS was significantly prolonged.
Improvement of PFS may also be an important finding,
because PFS is less prone to the influence of second-line
therapy than OS. More grade 1–2 and grade 3–4 haema-
tological toxicity as well as gastrointestinal toxicity
occurred with combination therapy compared with
monotherapy, which was in line with other combination
chemotherapy regimens including a fluoropyrimidine
combined with platinum compounds [36, 37], taxanes [38,
39] or irinotecan [37, 40].
Our study has some limitations. First, we did not take
specific dosing regimens into account, which could have
impacted our results. With pooled data analyses, including
meta-analysis, it is often not possible to investigate to what
extent dose differences may have influenced the results of
cFig. 4 Stratified overall survival (OS) results for S-1 combination
therapy versus S-1 monotherapy. Forest plot of OS results for S-1-
based combination therapy versus S-1 monotherapy stratified per
patient subgroup. For target tumour more than three studies are shown
because these studies included only patients with measurable lesions.
Pooled sample sizes are stated for S-1 combination therapy and S-1
monotherapy groups if separate sample sizes were not available in the
study report. CI confidence interval, Cis cisplatin, df degrees of
freedom, DTX docetaxel, E effect, ECOG Eastern Cooperative
Oncology Group performance status, H heterogeneity, HR hazard
ratio, IRI irinotecan, Ox oxaliplatin, PTX paclitaxel
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the meta-analysis. Also, in some studies, leucovorin was
added to fluoropyrimidine therapy. Leucovorin increases
the intracellular pool of 5,10-methylenetetrahydrofolate,
thereby enhancing thymidylate synthase inhibition by flu-
orodeoxyuridine monophosphate [41]. This mechanism of
action implies that leucovorin should be regarded not as an
additional cytotoxic agent but rather as a modulator of
fluoropyrimidine efficacy and toxicity. We conducted
sensitivity analyses in which we omitted the studies in
which leucovorin was concomitantly administrated with
one of the S-1 or 5-FU regimens. This did not affect the
pooled effect sizes of all comparisons. Furthermore, most
of the fluoropyrimidine dosing regimens of the studies
included in our review were similar. Especially the dosing
of S-1 is fairly constant among different studies.
A second limitation is that the heterogeneity due to the
difference in OS effect size in the Chinese subgroup and
Japanese subgroup may somewhat complicate the inter-
pretation of the S-1 combination therapy versus S-1
monotherapy analysis. Two of the Chinese studies were
single-centre studies, whereas all Japanese studies were
multicentre studies and therefore may have higher quality.
However, the sensitivity analysis according to the risk of
bias did not suggest major fluctuations in results. Whether
there is a real difference in efficacy for combination ther-
apy between Chinese and Japanese populations or whether
this is purely a methodological issue remains unclear and
should be addressed in larger and more qualitatively sound
studies with Chinese patients.
In summary, S-1-based therapy showed no difference in
survival compared with 5-FU- and capecitabine-based
therapy but has a higher ORR compared with 5-FU-based
therapy. In terms of clinical relevance, the toxicity profile
of S-1 compared with 5-FU was clearly more advantageous
in Western patients. Also, S-1 showed a better toxicity
profile compared with capecitabine, with a lower incidence
of hand–foot syndrome. In general, S-1 combination ther-
apy is superior to S-1 monotherapy in terms of efficacy,
and patients with poor prognosis disease characteristics
may benefit most from S-1 combination therapy, although
S-1 combinations were more toxic than S-1 alone. Our
findings suggest that S-1-based regimens are effective and
tolerable as first-line treatment of advanced gastric cancer
in both Asian and Western countries.
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Heterogeneity: I−squared=60.1%, tau−squared=0.0608, p=0.0815
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